Patent Cliff

The sharp decline in revenues that occurs when a major drug's patent expires, allowing cheaper generic alternatives to enter the market.

A patent cliff refers to the period when a pharmaceutical or biotechnology company's exclusive patent rights on one or more highly profitable "blockbuster" drugs expire. Once this legal protection ends, generic and biosimilar manufacturers are permitted to introduce identical or highly similar versions of the drug, typically at a fraction of the original price. This transition triggers a rapid shift in market dynamics. Because generic manufacturers do not need to recoup the massive research and development costs associated with discovering a new drug, they can price their products aggressively. This forces the original patent holder to either slash its own prices or cede the vast majority of its market share, leading to a steep drop in product revenue. For investors, a patent cliff represents a major structural risk that can severely impact a company's net income, cash flow, and valuation. To evaluate how well a drugmaker can withstand a patent cliff, analysts scrutinize its research and development pipeline, the schedule of upcoming patent expirations, and its strategic acquisitions of younger biotech firms with fresh intellectual property.

Company A generates $5,000,000,000 in annual revenue from its patented blockbuster drug, which represents 50% of its total sales. When the patent expires, generic competitors enter the market and price their alternatives 80% lower. Company A's sales of the drug fall to $1,000,000,000 within two years, resulting in a $4,000,000,000 drop in total company revenue.